HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

phenylalanyl(ornithinyl- prolyl- cyclohexylalanyl- tryptophyl- arginyl)

structure in first source

Also Known As:

F-(OPdChaWR); Phe-(Orn-Pro-D-cyclohexylalanine-Trp-Arg)

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Polycyclic Compounds: 6
- Macrocyclic Compounds: 15
  - Cyclic Peptides: 530
    - phenylalanyl(ornithinyl-prolyl-cyclohexylalanyl-tryptophyl-arginyl): 3
Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Cyclic Peptides: 530
    - phenylalanyl(ornithinyl-prolyl-cyclohexylalanyl-tryptophyl-arginyl): 3

Experts

1.	Arumugam, Thiruma V: 1 article (04/2002)
2.	Fairlie, David P: 1 article (04/2002)
3.	Reid, Robert C: 1 article (04/2002)
4.	Shiels, Ian A: 1 article (04/2002)
5.	Taylor, Stephen M: 1 article (04/2002)
6.	Woodruff, Trent M: 1 article (04/2002)
7.	Bignold, L P: 1 article (09/2000)
8.	Fairlie, D P: 1 article (09/2000)
9.	Harkin, D G: 1 article (09/2000)
10.	Haynes, D R: 1 article (09/2000)

Related Diseases

1.	Neutropenia 02/01/1999 - "Human recombinant C5a (2 microg kg(-1) i.v.) caused rapid neutropenia, characterized by an 83% decrease in circulating polymorphonuclear leukocytes (PMNs) at 5 min. Administration of F-[OPdChaWR] (0.3-3 mg kg(-1) i.v.), did not affect the levels of circulating PMNs but, when given 10 min prior to C5a, it inhibited the C5a-induced neutropenia by up to 70%. " 02/01/1999 - "Coli lipopolysaccharide (LPS, 1 mg kg(-1) i.v.) also caused neutropenia with an 88% decrease in circulating PMNs after 30 min. When rats were pretreated with F-[OPdChaWR] (0.3 - 10 mg kg(-1) i.v.) 10 min prior to LPS, there was a dose-dependent antagonism of the neutropenia caused by LPS, with up to 69% reversal of neutropenia observed 30 min after LPS administration. " 09/01/2000 - "A cyclic peptide, Phe-[Orn-Pro-D-Cyclohexylalanine-Trp-Arg] (F-[OPdChaWR]), was recently shown in vitro to antagonise the binding of C5a to its receptor (CD88) on human polymorphonuclear leukocytes (PMNs) and in vivo to inhibit the neutropenia associated with septic shock induced by lipopolysaccharide (LPS) in rats. "
2.	Wounds and Injuries (Trauma) 04/01/2002 - "We have studied the action of an orally active complement factor 5a (C5a) receptor antagonist, the cyclic peptide AcF-(OPdChaWR) [Ac-Phe(Orn-Pro-d-cyclohexylalanine-Trp-Arg)] against local and remote intestinal I/R injuries in rats. "
3.	Septic Shock (Toxic Shock Syndrome) 09/01/2000 - "A cyclic peptide, Phe-[Orn-Pro-D-Cyclohexylalanine-Trp-Arg] (F-[OPdChaWR]), was recently shown in vitro to antagonise the binding of C5a to its receptor (CD88) on human polymorphonuclear leukocytes (PMNs) and in vivo to inhibit the neutropenia associated with septic shock induced by lipopolysaccharide (LPS) in rats. "

Related Drugs and Biologics

1.	Cyclic Peptides
2.	Lipopolysaccharides
3.	phenylalanyl(ornithinyl- prolyl- cyclohexylalanyl- tryptophyl- arginyl)
4.	Anaphylatoxin C5a Receptor
5.	Factor Va
6.	Complement System Proteins (Complement)
7.	AcPhe(ornithine- Pro- cyclohexylamine- Trp- Arg)